Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study

Ruxolitinib improves splenomegaly and symptoms in patients with intermediate-2 or high-risk myelofibrosis; however, nearly half develop grade 3/4 anemia and/or thrombocytopenia, necessitating dose reductions a...

Source: Journal of Hematology and Oncology - August 7, 2018 Category: Hematology Authors: Moshe Talpaz, Susan Erickson-Viitanen, Kevin Hou, Solomon Hamburg and Maria R. Baer Tags: Research Source Type: research